Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., QIAGEN and others are Dominating the Market for Global Multiplex Assays Market in 2017

Thermo Fisher Scientific Inc.:

Thermo Fisher Scientific Inc., founded in 1956 and based in Massachusetts, U.S. The company provides manufacturing, distributing and services of medical devices and pharma Services. The Company has its business segments such as laboratory products & services, life sciences solutions, analytical instruments, and specialty diagnostics. The company has its presence in North America, Europe, Asia-Pacifica, and rest of World.

Access Full Report: https://databridgemarketresearch.com/reports/global-multiplex-assays-market/

In December 2017, New Salmonella Multiplex PCR Solution provided by Thermo Fisher Scientific that offered first validated assay for simultaneous detection of three salmonella targets in one rapid test. Hence company strengthened their footprint in market after providing validated product to their customers with has higher degree of better result.

Hoffmann-La Roche Ltd:

  1. Hoffmann-La Roche Ltd incorporated in 1896, headquarters in Switzerland, and focuses on developing innovative medicines and diagnostic tests. Company has two business segment and they are pharmaceuticals and diagnostics. The company has its presence in Europe, North America, Latin America, Asia, Africa, Australia and Oceania.

 In September 2014, F. Hoffmann-La Roche Ltd launched new fully automated molecular diagnostic systems named as cobas 6800/8800 Systems. These systems offer results in a very short time along with highest testing capacity. With this launch the company has increased their product portfolio in market in diagnostics field.. 

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. founded in 1952, headquartered in California, U.S. and focuses on manufacturing and supplying chemical component and products in life science research, analytical chemistry field. The company has it business segment and they are life science, clinical diagnostics and others.

The company has its presence in Europe, Pacific Rim, U.S. and others (primarily Canada and Latin America)

 In May 2018, Bio-Rad Laboratories, Inc. launched the Bio-Plex Pro Human Cytokine Screening Panel. This product is the first validated high-performance multiplex assay on the market. The panel has the ability to identify and quantify 48 different analytes. This is applicable for identification and estimation of analytes for heart disease, autoimmunity and allergy, cancer, and many other conditions. Launching this product helped the company in increasing their product portfolio.